BGM Group Ltd. (BGM)
6.38
-0.25
(-3.77%)
USD |
NASDAQ |
Dec 09, 15:17
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.280B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -21.91% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.615 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China. |
| URL | http://www.bgmgroupltd.com |
| Investor Relations URL | https://www.bgmgroupltd.com/investor-relations |
| HQ State/Province | Sichuan |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 22, 2026 (est.) |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 27, 2023 |
Ratings
Profile
| BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China. |
| URL | http://www.bgmgroupltd.com |
| Investor Relations URL | https://www.bgmgroupltd.com/investor-relations |
| HQ State/Province | Sichuan |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jan. 22, 2026 (est.) |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Feb. 27, 2023 |